BioCentury | Jun 14, 2017
Distillery Therapeutics

Neurology

...HspH1 promoter teprenone plus one of three drugs with depression as a side effect -- PegIntron...
...ribavirin is marketed to treat HCV. Enzon Pharmaceuticals Inc. and Merck & Co. Inc. market PegIntron...
BioCentury | Apr 18, 2016
Clinical News

Zepatier grazoprevir/elbasvir: Phase III data

...patients achieving an SVR 12 weeks after the end of treatment vs. Sovaldi sofosbuvir plus PegIntron...
...rates of 100%, 99% and 100%, respectively, vs. 100%, 90% and 60% for Sovaldi plus PegIntron...
...patients discontinued Zepatier due to serious treatment-related adverse events vs. 1 patient receiving Sovaldi plus PegIntron...
BioCentury | Mar 26, 2015
Translation in Brief

PK Gender Gap

...similar variability occurs in animal models. Her team set out to study the PK of PegIntron...
...actually quite big differences with pegylated interferon between male and female animals." In female mice, PegIntron...
BioCentury | May 12, 2014
Company News

Enzon infectious news

...common stock. Enzon has no ongoing clinical development but receives royalties on seven products, including PegIntron...
BioCentury | Apr 14, 2014
Clinical News

MK-5172: Phase II data

...and across multiple patient groups. MK-8742 is an oral HCV NS5A protein inhibitor. Merck markets PegIntron...
BioCentury | Mar 24, 2014
Clinical News

BIT225: Additional Phase II data

...HCV genotype 1 or 3 infection. Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets PegIntron...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

...Pfizer Express Scripts Interferon beta (MS) Betaseron interferon beta-1b Bayer Express Scripts Interferons (other immunological) PegIntron...
BioCentury | Dec 9, 2013
Clinical News

BIT225: Interim Phase II data

...HCV genotype 1 or 3 infection. Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets PegIntron...
BioCentury | May 6, 2013
Clinical News

Simeprevir: Additional Phase III data

...150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a and Copegus ribavirin or PegIntron...
...Basel, Switzerland) markets Pegasys and Copegus. Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J) markets PegIntron...
BioCentury | Apr 29, 2013
Finance

Highlights of weekly biotech stock moves

...serious hypersensitivity reactions. Enzon said the Omontys recall and the declining revenues of HCV drug PegIntron...
Items per page:
1 - 10 of 347